Mesenchymal stem cells (MSCs) directly differentiate into neurons and endothelial cells after transplantation, and their secretome has considerable potential for treating brain injuries. Previous studies have suggested that the effects of MSCs priming with exposure to hypoxia, cytokines, growth factors, or chemical agents could optimize the paracrine potency and therapeutic potential of MSCs. Studies have suggested that thrombin-primed Wharton's Jelly-derived mesenchymal stem cells (Th.WJ-MSCs) significantly enhance the neuroprotective beneficial effects of naive MSCs in brain injury such as hypoxic-ischemic brain injury (HIE) and intraventricular hemorrhage (IVH). This study aimed to characterize WJ-MSCs in terms of stem cell markers, differentiation, cell proliferation, and paracrine factors by comparing naive and Th.WJ-MSCs. We demonstrated that compared with naive MSCs, Th.MSCs significantly enhanced the neuroprotective effects in vitro. Moreover, we identified differentially expressed proteins in the conditioned media of naive and Th.WJ-MSCs by liquid chromatography-tandem mass spectrometry analysis. Secretome analysis of the conditioned medium of WJ-MSCs revealed that such neuroprotective effects were mediated by paracrine effects with secretomes of Th.WJ-MSCs, and hepatocyte growth factor was identified as a key paracrine mediator. These results can be applied further in the preclinical and clinical development of effective and safe cell therapeutics for brain injuries such as HIE and IVH.
Get full access to this article
View all access options for this article.
References
1.
MotYY, OthmanI and SharifahSH. (2017). Synergistic antibacterial effect of co-administering adipose-derived mesenchymal stromal cells and Ophiophagus hannah L-amino acid oxidase in a mouse model of methicillin-resistant Staphylococcus aureus-infected wounds. Stem Cell Res Ther, 8:5.
2.
ZolfagharM, MirzaeianL, BeikiB, NajiT, MoiniA, Eftekhari-YazdiP, AkbarinejadV, VernengoAJ and FathiR. (2020). Wharton's jelly derived mesenchymal stem cells differentiate into oocyte like cells in vitro by follicular fluid and cumulus cells conditioned medium. Heliyon, 6:e04992.
3.
ThomiG, SurbekD, HaeslerV, Joerger-MesserliM and SchoeberleinA. (2019). Exosomes derived from umbilical cord mesenchymal stem cells reduce microglia-mediated neuroinflammation in perinatal brain injury. Stem Cell Res Ther, 10:105.
4.
WilliamsAM, DennahyIS, BhattiUF, HalaweishI, XiongY, ChangP, NikolianVC, ChtraklinK, BrownJ, et al. (2019). Mesenchymal stem cell-derived exosomes provide neuroprotection and improve long-term neurologic outcomes in a swine model of traumatic brain injury and hemorrhagic shock. J Neurotrauma, 36:54–60.
5.
TaoH, HanZ, HanZC and LiZ. (2016). Proangiogenic features of mesenchymal stem cells and their therapeutic applications. Stem Cells Int, 2016:1314709.
6.
Prockop DJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science, 276:71–74.
7.
WangHS, HungSC, PengST, HuangCC, WeiHM, GuoYJ, FuYS, LaiMC and ChenCC. (2004). Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells, 22:1330–1337.
8.
WuKH, ZhouB, LuSH, FengB, YangSG, DuWT, GuDS, HanZC and LiuYL. (2007). In vitro and in vivo differentiation of human umbilical cord derived stem cells into endothelial cells. J Cell Biochem, 100:608–616.
9.
ParkWS, AhnSY, SungSI, AhnJY and ChangYS. (2018). Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders. Pediatr Res, 83:214–222.
10.
DoornJ, MollG, Le BlancK, van BlitterswijkC and de BoerJ. (2012). Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev, 18:101–115.
11.
LiaoW, XieJ, ZhongJ, LiuY, DuL, ZhouB, XuJ, LiuP, YangS, et al. (2009). Therapeutic effect of human umbilical cord multipotent mesenchymal stromal cells in a rat model of stroke. Transplantation, 87:350–359.
12.
ZhaoLR, DuanWM, ReyesM, KeeneCD, VerfaillieCM and LowWC. (2002). Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol, 174:11–20.
13.
XiongY, MahmoodA and ChoppM. (2010). Angiogenesis, neurogenesis and brain recovery of function following injury. Curr Opin Investig Drugs, 11:298–308.
14.
ChenJ and ChoppM. (2006). Neurorestorative treatment of stroke: cell and pharmacological approaches. NeuroRx, 3:466–473.
15.
RanganathSH, LevyO, InamdarMS and KarpJM. (2012). Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell, 10:244–258.
16.
KimYE, SungSI, ChangYS, AhnSY, SungDK and ParkWS. (2019). Thrombin preconditioning enhances therapeutic efficacy of human Wharton's jelly-derived mesenchymal stem cells in severe neonatal hypoxic ischemic encephalopathy. Int J Mol Sci, 20;20(10):2477.
17.
JungSY, KimYE, ParkWS, AhnSY, SungDK, SungSI, JooKM, KimSG and ChangYS. (2022). Thrombin preconditioning improves the therapeutic efficacy of mesenchymal stem cells in severe intraventricular hemorrhage induced neonatal rats. Int J Mol Sci 18;23(8):4447.
18.
SilvaLHA, AntunesMA, Dos SantosCC, WeissDJ, CruzFF and RoccoPRM. (2018). Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases. Stem Cell Res Ther, 9:45.
19.
SchaferR, SpohnG and BaerPC. (2016). Mesenchymal stem/stromal cells in regenerative medicine: can preconditioning strategies improve therapeutic efficacy?. Transfus Med Hemother, 43:256–267.
20.
GoldsackNR, ChambersRC, DabbaghK and LaurentGJ. (1998). Thrombin. Int J Biochem Cell Biol, 30:641–646.
21.
BoffaMC, JackmanRW, PeyriN, BoffaJF and GeorgeB. (1991). Thrombomodulin in the central nervous system. Nouv Rev Fr Hematol (1978), 33:423–429.
22.
FestoffBW and CitronBA. (2019). Thrombin and the coag-inflammatory nexus in neurotrauma, ALS, and other neurodegenerative disorders. Front Neurol, 10:59.
23.
VaughanPJ, PikeCJ, CotmanCW and CunninghamDD. (1995). Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci, 15:5389–5401.
24.
KarahuseyinogluS, CinarO, KilicE, KaraF, AkayGG, DemiralpDO, TukunA, UckanD and CanA. (2007). Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells, 25:319–331.
25.
SagaradzeG, GrigorievaO, NimiritskyP, BasalovaN, KalininaN, AkopyanZ and EfimenkoA. (2019). Conditioned medium from human mesenchymal stromal cells: towards the clinical translation. Int J Mol Sci, 20:1656.
26.
KimSS, PyeonHJ, BaeYK, NamH, KimCK, LeeSH and JooKM. (2021). Adult human multipotent neural cells could be distinguished from other cell types by proangiogenic paracrine effects via MCP-1 and GRO. Stem Cells Int, 2021:6737288.
27.
HaGH, KimEJ, ParkJS, KimJE, NamH, YeonJY, LeeSH, LeeK, KimCK and JooKM. (2022). JAK2/STAT3 pathway mediates neuroprotective and pro-angiogenic treatment effects of adult human neural stem cells in middle cerebral artery occlusion stroke animal models. Aging (Albany NY), 14:8944–8969.
28.
JeonYK, KimCK, HwangKR, ParkHY, KohJ, ChungDH, LeeCW and HaGH. (2017). Pellino-1 promotes lung carcinogenesis via the stabilization of Slug and Snail through K63-mediated polyubiquitination. Cell Death Differ, 24:469–480.
29.
Jeong-Hun MokMJ, Van-An Duong, Seonghyeon Cho, Jong-Moon Park, Young-Sic Eom, Tae-Hwa Song, Hee-Joung Lim, and LeeHookeun (2021). Proteomic and metabolomic analyses of maggots in porcine corpses for post-mortem interval estimation. Appl Sci, 11:7885.
30.
NohJH, JeongJS, ParkSJ, Jin JungK, LeeBS, KimWJ, HanJS, ChoMK, SungDK, et al. (2021). Preclinical assessment of thrombin-preconditioned human Wharton's jelly-derived mesenchymal stem cells for neonatal hypoxic-ischaemic brain injury. J Cell Mol Med, 25:10430–10440.
31.
ParekkadanB and MilwidJM. (2010). Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng, 12:87–117.
32.
NajarM, RaicevicG, Fayyad-KazanH, BronD, ToungouzM and LagneauxL. (2016). Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy, 18:160–171.
33.
MunnDH and MellorAL. (2013). Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol, 34:137–143.
JungW, CastrenE, OdenthalM, Vande WoudeGF, IshiiT, DienesHP, LindholmD and SchirmacherP. (1994). Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J Cell Biol, 126:485–494.
36.
EbensA, BroseK, LeonardoED, Hanson JrMG., BladtF, BirchmeierC, BarresBA and Tessier-LavigneM. (1996). Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron, 17:1157–1172.
37.
WongWK, CheungAW, YuSW, ShaO and ChoEY. (2014). Hepatocyte growth factor promotes long-term survival and axonal regeneration of retinal ganglion cells after optic nerve injury: comparison with CNTF and BDNF. CNS Neurosci Ther, 20:916–929.
38.
PonzettoC, BardelliA, MainaF, LongatiP, PanayotouG, DhandR, WaterfieldMD and ComoglioPM. (1993). A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. Mol Cell Biol, 13:4600–4608.
39.
XiaoGH, JeffersM, BellacosaA, MitsuuchiY, Vande WoudeGF and TestaJR. (2001). Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A, 98:247–252.
40.
BoccaccioC, AndoM, TamagnoneL, BardelliA, MichieliP, BattistiniC and ComoglioPM. (1998). Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 391:285–288.
41.
MatsumuraA, KubotaT, TaiyohH, FujiwaraH, OkamotoK, IchikawaD, ShiozakiA, KomatsuS, NakanishiM, et al. (2013). HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. Int J Oncol, 42:535–542.
42.
TrusolinoL and ComoglioPM. (2002). Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer, 2:289–300.
43.
Carreno-MullerE, HerreraAJ, de PablosRM, Tomas-CamardielM, VeneroJL, CanoJ and MachadoA. (2003). Thrombin induces in vivo degeneration of nigral dopaminergic neurones along with the activation of microglia. J Neurochem, 84:1201–1214.
44.
FestoffBW, AmeenuddinS, SantacruzK, MorserJ, SuoZ, ArnoldPM, StrickerKE and CitronBA. (2004). Neuroprotective effects of recombinant thrombomodulin in controlled contusion spinal cord injury implicates thrombin signaling. J Neurotrauma, 21:907–922.
45.
MasadaT, XiG, HuaY and KeepRF. (2000). The effects of thrombin preconditioning on focal cerebral ischemia in rats. Brain Res, 867:173–179.
46.
XiG, KeepRF, HuaY, XiangJ and HoffJT. (1999). Attenuation of thrombin-induced brain edema by cerebral thrombin preconditioning. Stroke, 30:1247–1255.
47.
LeeKR, BetzAL, KimS, KeepRF and HoffJT. (1996). The role of the coagulation cascade in brain edema formation after intracerebral hemorrhage. Acta Neurochir (Wien), 138:396–400; discussion 400–401.
48.
XiG, WagnerKR, KeepRF, HuaY, de Courten-MyersGM, BroderickJP, BrottTG and HoffJT. (1998). Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke, 29:2580–2586.
49.
XiG, ReiserG and KeepRF. (2003). The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective?. J Neurochem, 84:3–9.
50.
YeF, GartonHJL, HuaY, KeepRF and XiG. (2021). The role of thrombin in brain injury after hemorrhagic and ischemic stroke. Transl Stroke Res, 12:496–511.
51.
AhnSY, SungDK, KimYE, SungS, ChangYS and ParkWS. (2021). Brain-derived neurotropic factor mediates neuroprotection of mesenchymal stem cell-derived extracellular vesicles against severe intraventricular hemorrhage in newborn rats. Stem Cells Transl Med, 10:374–384.
52.
AhnSY, SungDK, ChangYS, SungSI, KimYE, KimHJ, LeeSM and ParkWS. (2021). BDNF-overexpressing engineered mesenchymal stem cells enhances their therapeutic efficacy against severe neonatal hypoxic ischemic brain injury. Int J Mol Sci. 22.
53.
DelavogiaE, NtentakisDP, CortinasJA, Fernandez-GonzalezA, Alex MitsialisS and KourembanasS. (2022). Mesenchymal stromal/stem cell extracellular vesicles and perinatal injury: one formula for many diseases. Stem Cells, 40:991–1007.
54.
ChanAML, SampasivamY and LokanathanY. (2022). Biodistribution of mesenchymal stem cells (MSCs) in animal models and implied role of exosomes following systemic delivery of MSCs: a systematic review. Am J Transl Res, 14:2147–2161.
55.
IslamovRR, RizvanovAA, FedotovaVY, IzmailovAA, SafiullovZZ, GaraninaEE, SalafutdinovII, SokolovME, MukhamedyarovMA and PalotasA. (2017). Tandem delivery of multiple therapeutic genes using umbilical cord blood cells improves symptomatic outcomes in ALS. Mol Neurobiol, 54:4756–4763.
56.
SensebeL and Fleury-CappellessoS. (2013). Biodistribution of mesenchymal stem/stromal cells in a preclinical setting. Stem Cells Int, 2013:678063.
57.
KyurkchievD, BochevI, Ivanova-TodorovaE, MourdjevaM, OreshkovaT, BelemezovaK and KyurkchievS. (2014). Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells, 6:552–570.
58.
XunC, GeL, TangF, WangL, ZhuoY, LongL, QiJ, HuL, DuanD, ChenP and LuM. (2020). Insight into the proteomic profiling of exosomes secreted by human OM-MSCs reveals a new potential therapy. Biomed Pharmacother, 131:110584.
59.
HanY, YangJ, FangJ, ZhouY, CandiE, WangJ, HuaD, ShaoC and ShiY. (2022). The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther, 7:92.
60.
SonJW, ParkJ, KimYE, HaJ, ParkDW, ChangMS and KohSH. (2019). Glia-like cells from late-passage human MSCs protect against ischemic stroke through IGFBP-4. Mol Neurobiol, 56:7617–7630.
61.
FurgeKA, ZhangYW and Vande WoudeGF. (2000). Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene, 19:5582–5589.
62.
BirchmeierC, BirchmeierW, GherardiE and Vande WoudeGF. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol, 4:915–925.
63.
GiordanoS, MaffeA, WilliamsTA, ArtigianiS, GualP, BardelliA, BasilicoC, MichieliP and ComoglioPM. (2000). Different point mutations in the met oncogene elicit distinct biological properties. FASEB J, 14:399–406.
64.
DziennisS and AlkayedNJ. (2008). Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration. Rev Neurosci, 19:341–361.
